Related Experiment Video
Updated: Jun 15, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Suppressors of cytokine signaling abrogate diabetic nephropathy
Guadalupe Ortiz-Muñoz1, Virginia Lopez-Parra, Oscar Lopez-Franco
1Renal and Vascular Research Laboratory, Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Abstract:
Activation of Janus kinase/signal transducers and activators of transcription (JAK/STAT) is an important mechanism by which hyperglycemia contributes to renal damage, suggesting that modulation of this pathway may prevent renal and vascular complications of diabetes. Here, we investigated the involvement of suppressors of cytokine signaling (SOCS) as intracellular negative regulators of JAK/STAT activation in diabetic nephropathy. In a rat model, inducing diabetes resulted in JAK/STAT activation and increased expression of SOCS1 and SOCS3. In humans, we observed increased expression of glomerular and tubulointerstitial SOCS proteins in biopsies of patients with diabetic nephropathy. In vitro, high concentrations of glucose activated JAK/STAT/SOCS in human mesangial and tubular cells. Overexpression of SOCS reversed the glucose-induced activation of the JAK/STAT pathway, expression of STAT-dependent genes (chemokines, growth factors, and extracellular matrix proteins), and cell proliferation. In vivo, intrarenal delivery of adenovirus expressing SOCS1 and SOCS3 to diabetic rats significantly improved renal function and reduced renal lesions associated with diabetes, such as mesangial expansion, fibrosis, and influx of macrophages. SOCS gene delivery also decreased the activation of STAT1 and STAT3 and the expression of proinflammatory and profibrotic proteins in the diabetic kidney. In summary, these results provide direct evidence for a link between the JAK/STAT/SOCS axis and hyperglycemia-induced cell responses in the kidney. Suppression of the JAK/STAT pathway by increasing intracellular SOCS proteins may have therapeutic potential in diabetic nephropathy.
Insights
Suppressors of cytokine signaling (SOCS) proteins can block Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway activation. Increasing SOCS may prevent kidney damage in diabetic nephropathy.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Hyperglycemia-induced Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway activation contributes to diabetic kidney damage.
- Suppressors of cytokine signaling (SOCS) proteins are intracellular negative regulators of JAK/STAT signaling.
- The role of SOCS in diabetic nephropathy remains to be fully elucidated.
Purpose of the Study:
- To investigate the involvement and therapeutic potential of SOCS proteins in diabetic nephropathy.
- To determine if SOCS can counteract hyperglycemia-induced JAK/STAT activation and kidney damage.
Main Methods:
- Utilized a rat model of diabetes and human kidney cells (mesangial and tubular).
- Measured JAK/STAT pathway activation, SOCS expression (SOCS1 and SOCS3), and STAT-dependent gene expression.
- Administered adenovirus expressing SOCS1 and SOCS3 intrarenally in diabetic rats.
- Assessed renal function, kidney lesions, and inflammatory/fibrotic markers.
Main Results:
- Diabetes induced JAK/STAT activation and increased SOCS1/SOCS3 expression in rats and human kidney cells.
- High glucose activated JAK/STAT/SOCS in vitro; SOCS overexpression reversed glucose-induced effects.
- Intrarenal SOCS gene delivery improved renal function and reduced kidney lesions in diabetic rats.
- SOCS delivery decreased STAT activation and proinflammatory/profibrotic protein expression.
Conclusions:
- A link exists between the JAK/STAT/SOCS axis and hyperglycemia-induced kidney cell responses.
- SOCS proteins act as negative regulators of the JAK/STAT pathway in diabetic nephropathy.
- Enhancing intracellular SOCS may offer a therapeutic strategy for diabetic kidney disease.
Related Concept Videos
Diabetic Nephropathy
Type I Diabetes II: Pathophysiology
Diabetic Neuropathy
Type II Diabetes II: Pathophysiology